Premium
High‐dose‐rate brachytherapy for intranasal tumours in dogs: results of a pilot study
Author(s) -
Klueter S.,
Krastel D.,
Ludewig E.,
Reischauer A.,
Heinicke F.,
Pohlmann S.,
Wolf U.,
Grevel V.,
Hildebrandt G.
Publication year - 2006
Publication title -
veterinary and comparative oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.864
H-Index - 34
eISSN - 1476-5829
pISSN - 1476-5810
DOI - 10.1111/j.1476-5829.2006.00109.x
Subject(s) - medicine , brachytherapy , adverse effect , nasal administration , toxicity , prospective cohort study , magnetic resonance imaging , surgery , nuclear medicine , radiation therapy , radiology , immunology
This prospective study describes the feasibility and toxicity of 192 Iridium high‐dose‐rate (HDR) brachytherapy as an alternative strategy for the treatment of canine intranasal tumours. Fifteen dogs with malignant intranasal tumours were treated twice weekly using a hypofractionated protocol with eight fractions, 5 Gy per fraction, resulting in a total dose of 40 Gy. Acute and chronic adverse side‐effects appeared to be rare. Only 7% of the acute side‐effects and 5% of the chronic were classified as severe (grade 3). Eight dogs showed clinical complete remission, and five dogs had partial remission, with a resolution of tumour‐related symptoms. Magnetic resonance imaging showed a reduced tumour mass in 12 cases. Median survival time was 17 months (range 4–48 months), with four dogs (three without disease) still alive. Median time to recurrence of these dogs was 14 months. In nine dogs, progression or recurrence of the tumour was the cause of death. This study suggests that HDR brachytherapy is feasible and well tolerated.